1638497-22-9

Basic information

• Product Name: Avanafil iMpurity
• Synonyms: Avanafil iMpurity;Deschloro Avanafil
• CAS NO: 1638497-22-9
• Molecular Formula: C20H25ClN4O4
• Molecular Weight: 420.89
• Mol File: 1638497-22-9.mol
• Article Data: 15

Chemical Properties

• Boiling Point: 607.5±65.0 °C(Predicted)
• Appearance: /
• Density: 1.317±0.06 g/cm3(Predicted)
• PKA: 14.77±0.10(Predicted)
• CAS DataBase Reference: Avanafil iMpurity(CAS DataBase Reference)
• NIST Chemistry Reference: Avanafil iMpurity(1638497-22-9)
• EPA Substance Registry System: Avanafil iMpurity(1638497-22-9)

Safety Data

• Hazardous Substances Data: 1638497-22-9(Hazardous Substances Data)

Upstream product

• 68832-13-3 D-prolinol 
• 372117-76-5 2-methylsulfonyl-5-ethoxycarbonyl-4-(3-chloro-4-methoxybenzylamino)pyrimidine 
• 115514-77-7 (3-chloro-4-methoxyphenyl)methanamine 
• 330785-81-4 ethyl 4-[(3-chloro-4-methoxybenzyl)amino]-2-(methylsulfanyl)pyrimidine-5-carboxylate 
• 5909-24-0 4-chloro-2-methanesulfanylpyrimidine-5-carboxylic acid ethyl ester 
• 330785-82-5 4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonyl-2-methylsulfinylpyrimidine 
• 23356-96-9 (S)-1-Pyrrolidin-2-yl-methanol 
• 28485-17-8 5-carbethoxyuracil 
• 41965-95-1 (3-chloro-4-methoxyphenyl)methylamine hydrogen chloride 
• 51940-64-8 ethyl 2,4-dichloropyrimidine-5-carboxylate 
• 147-85-3 L-proline 
• 53554-29-3 ethyl 4-hydroxy-2-(methylthio)pyrimidine-5-carboxylate 
• 87-13-8 diethyl 2-ethoxymethylenemalonate 
• 330785-99-4 2-hydroxy-4-(3-chloro-4-methoxybenzylamino)-5-ethoxycarbonylpyrimidine 

Downstream Products

• 330784-47-9 avanafil 

Relevant articles and documents

A kind of avanafil impurity D and synthesis method and application thereof

The present invention provides a new aphranarfil impurity and synthesis method thereof, by synthesizing and characterizing the impurity, the structure of the impurity is determined, the drug impurity profile of avanafil is perfected, the resulting product is of high purity, can be used as a control for drug quality control research.

Method of preparing medical compound stendra

The invention discloses a method of preparing a medical compound stendra and belongs to the technical field of medical compounds. The key point of the technical scheme is as follows: the synthetic route of the method of preparing the medical compound stendra is as follows: a formula as shown in the description. The method has the advantages of being high in yield, low in cost, economical and environment-friendly, suitable for industrialization, high in product impurity and the like, and is a synthetic method which has industrial production value.

Atorvastatin that non-preparation method

The invention relates to a preparation method of avanafil and a new compound provided in a preparation process. According to the method, 5-uracil carboxylic acid or an ester thereof is taken as the raw material, and the avanafil meeting the clinical requirements can be synthesized at a relatively cost; besides, the preparation method is simple and convenient to operate, mild in reaction conditions, high in yield, low in cost, environmentally friendly and suitable for industrial large-scale production of the avanafil.